1Ab Therapeutics

1Ab Therapeutics is a pre-clinical stage biotechnology company focused on developing a new class of antibody therapeutics that target the intracellular proteome. By leveraging its proprietary platform, the company engineers antibodies that recognize peptide-MHC complexes, effectively allowing antibodies to access targets previously considered undruggable. This approach combines the specificity of monoclonal antibodies with the broad target range of T-cell receptors. The company's primary focus is on oncology and autoimmune diseases, where it aims to provide first-in-class treatments for patients with high unmet medical needs.